These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29885868)

  • 1. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: Mortality and prognostic factors.
    Callejas-Díaz A; Fernández-Pérez C; Ramos-Martínez A; Múñez-Rubio E; Sánchez-Romero I; Vargas Núñez JA
    Med Clin (Barc); 2019 Feb; 152(3):83-89. PubMed ID: 29885868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
    Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
    Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.
    Dantas RC; Ferreira ML; Gontijo-Filho PP; Ribas RM
    J Med Microbiol; 2014 Dec; 63(Pt 12):1679-1687. PubMed ID: 25261066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
    Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
    Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
    Balandin B; Ballesteros D; Ruiz de Luna R; López-Vergara L; Pintado V; Sancho-González M; Soriano-Cuesta C; Pérez-Pedrero MJ; Asensio-Martín MJ; Fernández-Simón I; Rodríguez-Serrano D; Silva A; Chicot M; Iranzo R; Martínez-Sagasti F; Royuela A
    Int J Antimicrob Agents; 2021 Mar; 57(3):106270. PubMed ID: 33347991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
    Gentry CA; Williams RJ
    Int J Antimicrob Agents; 2017 Mar; 49(3):333-338. PubMed ID: 28108367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
    Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
    BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.
    Hattemer A; Hauser A; Diaz M; Scheetz M; Shah N; Allen JP; Porhomayon J; El-Solh AA
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3969-75. PubMed ID: 23733476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characterization of breakthrough bacteraemia: a survey of 392 episodes.
    López Dupla M; Martinez JA; Vidal F; Almela M; López J; Marco F; Soriano A; Richart C; Mensa J
    J Intern Med; 2005 Aug; 258(2):172-80. PubMed ID: 16018794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
    Albasanz-Puig A; Gudiol C; Parody R; Tebe C; Akova M; Araos R; Bote A; Brunel AS; Calik S; Drgona L; García E; Hemmati P; Herrera F; Ibrahim KY; Isler B; Kanj S; Kern W; Maestro de la Calle G; Manzur A; Marin JI; Márquez-Gómez I; Martín-Dávila P; Mikulska M; Montejo JM; Montero M; Morales HMP; Morales I; Novo A; Oltolini C; Peghin M; Del Pozo JL; Puerta-Alcalde P; Ruiz-Camps I; Sipahi OR; Tilley R; Yáñez L; Gomes MZR; Carratalà J;
    BMJ Open; 2019 May; 9(5):e025744. PubMed ID: 31129580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Clin Microbiol Infect; 2005 May; 11(5):415-8. PubMed ID: 15819873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of an early intervention programme for patients with bacteraemia: analysis of prognostic factors and mortality.
    Del Arco A; Olalla J; de la Torre J; Blázquez A; Montiel-Quezel N; Prada JL; Rivas F; García-Alegría J; Fernández-Sánchez F
    BMC Infect Dis; 2017 May; 17(1):360. PubMed ID: 28532458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance profiles and risk factors of resistant microorganisms in bacteraemia of abdominal origin.
    Martín Jaramago J; Armero Ibáñez R; Camarena Miñana JJ; Morales Suárez-Varela M
    Rev Esp Anestesiol Reanim; 2017 Nov; 64(9):490-498. PubMed ID: 28434558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.
    Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Fattah MA; Haquin J; MacGowan A; Grier S; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Maurer S; Rodriguez-Bano J; Morales I; Oliver A; de Gopegui ER; Cano A; Machuca I; Gozalo-Marguello M; Martinez-Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
    Int J Antimicrob Agents; 2020 Feb; 55(2):105847. PubMed ID: 31770625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.